Mario Perro

8PUBLICATIONS
50CO-AUTHORS
Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)BiomaterialsMedical mycologyCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Jun 12, 2026
Tobemstomig, a Novel Bispecific Antibody, Preferentially Blocks PD-1 and LAG-3 on CD8 TILs to Expand Stem-like T Cells for Sustained Tumor Control.

|Sep 11, 2024
ISB 2001 trispecific T cell engager shows strong tumor cytotoxicity and overcomes immune escape mechanisms of multiple myeloma cells.

Laura Carretero-Iglesia, Olivia J Hall, Jérémy Berret

|Mar 06, 2024
Development of ISB 1442, a CD38 and CD47 bispecific biparatopic antibody innate cell modulator for the treatment of multiple myeloma.

C Grandclément, C Estoppey, E Dheilly

|May 16, 2023
Preclinical characterization of ISB 1342, a CD38 × CD3 T-cell engager for relapsed/refractory multiple myeloma.

Blandine Pouleau, Carole Estoppey, Perrine Suere

|Mar 27, 2021
Fibroblast Activation Protein α-Targeted CD40 Agonism Abrogates Systemic Toxicity and Enables Administration of High Doses to Induce Effective Antitumor Immunity.

Eva Sum, Moritz Rapp, Philipp Fröbel

|Jan 06, 2021
Cross-linking of T cell to B cell lymphoma by the T cell bispecific antibody CD20-TCB induces IFNγ/CXCL10-dependent peripheral T cell recruitment in humanized murine model.

Floriana Cremasco, Elena Menietti, Dario Speziale

Pageof 2

Frequent Collaborators

3 joint publications

Thierry Monney

2 joint publications

Thomas Matthes

2 joint publications

Claire M Edwards

2 joint publications

James R Edwards